BMO Capital Maintains Their Buy Rating on Viking Therapeutics (VKTX)

In a report released today, Matthew Luchini from BMO Capital maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $15.00. The company's shares closed last Thursday at $6.40. According to TipRanks.com, Luchini is a 4-star analyst with an average return of 11.5% and a 52.8% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Applied Genetic Technologies, and Arvinas Holding Company. Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.10, implying a 135.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $21.00 price target. See today’s analyst top recommended stocks >> Viking Therapeutics' market cap is currently $499.8M and has a P/E ratio of -10.10. The company has a Price to Book ratio of 2.00. Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VKTX in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. The post BMO Capital Maintains Their Buy Rating on Viking Therapeutics (VKTX) appeared first on TipRanks Financial Blog.

In a report released today, Matthew Luchini from BMO Capital maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $15.00. The company's shares closed last Thursday at $6.40.

According to TipRanks.com, Luchini is a 4-star analyst with an average return of 11.5% and a 52.8% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Applied Genetic Technologies, and Arvinas Holding Company.

Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.10, implying a 135.9% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $21.00 price target.

Viking Therapeutics' market cap is currently $499.8M and has a P/E ratio of -10.10. The company has a Price to Book ratio of 2.00.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VKTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

The post BMO Capital Maintains Their Buy Rating on Viking Therapeutics (VKTX) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Metalla Royalty & Streaming (MTA) Receives a Hold from BMO Capital

In a report released today, Rene Cartier from BMO Capital maintained a Hold rating on Metalla Royalty & Streaming (MTA – Research Report), with a price target of $15.00. The company's shares closed last Thursday at $10.15. According to TipRanks.com, Cartier is a 5-star analyst with an average return of 53.9% and a 62.5% success rate. Cartier covers the Basic Materials sector, focusing on stocks such as Capstone Mining, Sandstorm Gold, and Taseko Mines. Currently, the analyst consensus on Metalla Royalty & Streaming is a Moderate Buy with an average price target of $13.20. See today’s analyst top recommended stocks >> The company has a one-year high of $13.50 and a one-year low of $5.06. Currently, Metalla Royalty & Streaming has an average volume of 250.8K. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Metalla Royalty & Streaming Ltd. engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It focuses on producing endeavor and NLGM silver stream; development of Joaquin, Santa Gertrudis, Garrison, Hoyle Pond Extension, West Timmins Extension, and Zaruma royalties; and exploration of Akasaba West and DeSantis Mine royalties. The company was founded on May 11, 1983 and is headquartered in Vancouver, Canada. The post Metalla Royalty & Streaming (MTA) Receives a Hold from BMO Capital appeared first on TipRanks Financial Blog.

In a report released today, Rene Cartier from BMO Capital maintained a Hold rating on Metalla Royalty & Streaming (MTA – Research Report), with a price target of $15.00. The company's shares closed last Thursday at $10.15.

According to TipRanks.com, Cartier is a 5-star analyst with an average return of 53.9% and a 62.5% success rate. Cartier covers the Basic Materials sector, focusing on stocks such as Capstone Mining, Sandstorm Gold, and Taseko Mines.

Currently, the analyst consensus on Metalla Royalty & Streaming is a Moderate Buy with an average price target of $13.20.

The company has a one-year high of $13.50 and a one-year low of $5.06. Currently, Metalla Royalty & Streaming has an average volume of 250.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Metalla Royalty & Streaming Ltd. engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It focuses on producing endeavor and NLGM silver stream; development of Joaquin, Santa Gertrudis, Garrison, Hoyle Pond Extension, West Timmins Extension, and Zaruma royalties; and exploration of Akasaba West and DeSantis Mine royalties. The company was founded on May 11, 1983 and is headquartered in Vancouver, Canada.

The post Metalla Royalty & Streaming (MTA) Receives a Hold from BMO Capital appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.